Skip to main content

$0.038 0.001 (2.70%)

High

$0.04

Low

$0.04

Trades

17

Turnover

$72,787

Volume

1,963,571
30 June 2023 at 3:59pm
Register to track CHM and receive email alerts.
Subject
CHM Ann: Change of Registry Address

CHM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CHM Ann: Notice of Annual General Meeting/Proxy Form

CHM Ann: ESG Report

CHM Ann: Appendix 4G

CHM Ann: Annual Report to shareholders

CHM Ann: Corporate Governance Statement

CHM Ann: Notification regarding unquoted securities - CHM

CHM Ann: Dr Stephanie H. Astrow appointed VP, Translational Sciences

CHM Ann: Appendix 4E and Preliminary Final Report

CHM Ann: Response to ASX Query

CHM Ann: Patent received in Japan for CLTX CAR technology

CHM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CHM Ann: Cell therapy industry leader appointed Chief Medical Officer

CHM Ann: Change of Director's Interest Notice - GM

CHM Ann: Appointment of VP Clinical Operations & Data Management

CHM Ann: Change of Director's Interest Notice - LC

CHM Ann: Application for quotation of securities - CHM

CHM Ann: Licenses viral vector technology from Penn for CDH17

CHM Ann: Notification regarding unquoted securities - CHM

CHM Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib

CHM Ann: Notice under section 708A

CHM Ann: Notification regarding unquoted securities - CHM

CHM Ann: Application for quotation of securities - CHM

CHM Ann: Key manufacturing milestone successfully completed

CHM Ann: Proposed issue of securities - CHM

CHM Ann: A$30 million Equity Placement Agreement with L1 Capital

CHM Ann: Notification of cessation of securities - CHM

CHM Ann: Exclusive option exercised for CORE-NK platform

CHM Ann: Virtual investor conference presentation 2 May 2022

CHM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

CHM Ann: Strategic manufacturing partnership with WuXi ATU

CHM Ann: Change of Director's Interest Notice - GM

CHM Ann: Change of Director's Interest Notice - CE

CHM Ann: Change of Director's Interest Notice - PH

CHM Ann: Change of Director's Interest Notice - LC

CHM Ann: Appendix 2A

CHM Ann: Security Class Reinstatement to Quotation CHMO

CHM Ann: Entitlement Offer Option Exercise Form

CHM Ann: Appendix 2A (amended)

CHM Ann: Appendix 2A

CHM Ann: Placement of Entitlement Offer Shortfall

CHM Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER

CHM Ann: Trading Halt

CHM Ann: Pause in Trading

CHM Ann: Completion of retail component of Entitlement Offer

CHM Ann: Security Class Suspension from Quotation CHMO

CHM Ann: Appendix 3B (amended)

CHM Ann: Extension of Closing Date for Retail Entitlement Offer

CHM Ann: Final Results in Phase 1 Trial of CORE NK Platform

Register to track CHM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX